幼年型粒单核细胞白血病预后指标研究进展  

Advances in prognostic indicators of juvenile myelomonocytic leukemia

作　　者：刘晨梦(综述) 杨文钰(审校) Liu Chenmeng;Yang Wenyu(State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China;Tianjin Institutes of Health Science,Tianjin 301600,China)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所),实验血液学国家重点实验室,国家血液系统疾病临床医学研究中心细胞生态海河实验室,天津300020 [2]天津医学健康研究院,301600

出　　处：《国际儿科学杂志》2023年第12期810-814,共5页International Journal of Pediatrics

摘　　要：幼年型粒单核细胞白血病(juvenile myelomonocytic leukemia,JMML)是一种罕见的恶性造血系统疾病,主要发生于婴幼儿阶段。JMML在临床上表现出高度的异质性,大多数患者病情进展迅速,预后不良;但也有少数患者的病情进展缓慢,甚至可自发缓解。影响JMML患者预后的指标包括临床特征、血液学检查指标、多种基因突变、急性髓系白血病样基因表达谱以及表观遗传学改变等因素。寻找JMML预后指标并进行风险分组,对于评估JMML的预后并制定个体化治疗方案具有重要意义。该文将对JMML预后指标的研究进展进行综述。Juvenile myelomonocytic leukemia(JMML)is a rare hematopoietic malignant disease that occurs mostly in infants and young children.JMML is clinically heterogeneous,with most patients having rapid progression and a poor prognosis.A minority of patients have slow progression and may achieve spontaneous remission.Indicators affecting the prognosis of patients include clinical features,hematologic indicators,genetic mutations,acute myeloid leukemia-like gene expression profiles,and epigenetic alterations.Finding JMML prognostic indicators for risk grouping is of great significance for prognostic assessment and individualized therapy.This paper aims to review the advances in prognostic indicators of JMML.

关 键 词：儿童 幼年型粒单核细胞白血病 预后指标 

分 类 号：R733.7[医药卫生—肿瘤]